Get started
RocketTickers

FDA Approves QULIPTA™ (atogepant), the First and Only Oral CGRP

Long
AbbVie Inc. (NYSE:ABBV)  
RocketTickers  
NYSE:ABBV   AbbVie Inc.
Beyond Technical Analysis
0
0
beyondta
ABBV: AbbVie
2021-09-28 18:00:00
FDA Approves QULIPTA™ (atogepant), the First and Only Oral CGRP Receptor Antagonist Specifically Developed for the Preventive Treatment of Migraine
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.